Last month, the US District Court for the District of Columbia struck down a 2013 policy issued by the US Department of Health and Human Services Health Resources and Services Administration (HRSA) ...

Pharmaceutical company Novartis has filed a lawsuit against the HHS over the way drugs are priced under the 340B program. The company is challenging the “product replenishment model,” which requires ...

Four drug manufacturers have announced plans to offer discounted drug prices to safety net providers under the federal 340B program via rebates instead of upfront discounts, despite the federal ...

Bristol Myers Squibb became the latest large drugmaker to sue the federal government over a plan to change how it doles out drug discounts to hospitals. Johnson & Johnson and Eli Lilly both filed ...

A federal court has rejected a lawsuit by several drugmakers that sought to change the 340B Drug Pricing Program from an upfront payment model to a backend rebate structure. Thursday's decision in U.S ...

A second pharmaceutical giant is suing the federal government over 340B program change denials this week. Lilly filed a lawsuit Nov. 14 against HHS head Xavier Becerra and the Health Resources and ...

Johnson & Johnson is backing down from using its planned rebate model in the 340B program. In a September 30 letter to the Health Resource and Services Administration, J&J said it would not implement ...